Judith L Treadway

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

In Vivo Imaging of Endogenous Pancreatic β-Cell Mass in Healthy and Type 1 Diabetic Subjects Using 18F-Fluoropropyl-Dihydrotetrabenazine and PET

Richard E Carson, Shu-Fei Lin, Krista Fowles, 2012, The Journal of Nuclear Medicine.

(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.

Zhengrong Zhao, Dennis E Danley, M. Ammirati, 2007, Bioorganic & medicinal chemistry letters.

Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase.

David G Myszka, Dennis E Danley, R. Fletterick, 2002, Chemistry & biology.